An at-home HPV test changes where a patient collects a cervical screening sample. It does not alter how the specimen is analyzed in the laboratory or what clinical steps follow an abnormal finding.
The Verdict
What At-Home HPV Testing Means in Practice
The first route relies on the Teal Wand from Teal Health. The company states the device is authorized by the US FDA and available across all 50 states through a virtual consultation with a Teal Medical provider. The second route centers on the Onclarity HPV Self-Collection Kit from Waters Corporation. On 8 April 2026, the FDA cleared the Onclarity kit and approved the BD Onclarity HPV Assay for at-home specimen collection.
Both pathways preserve standard clinical oversight. A patient swabs at home, packages the sample, and mails it directly to a laboratory. The laboratory runs molecular diagnostic assays to detect high-risk viral genetic material. Clinicians receive the final report to guide subsequent care. What changed is the collection setting. Clinical follow-up remains unchanged. An abnormal screening result still requires in-person medical evaluation and direct provider management.
The comparison below lists the two routes alphabetically by company; the order is not a ranking.
| Screening Route | Device or Collection Method | Laboratory Assay | Regulatory Status | Service Model |
|---|---|---|---|---|
| Teal Wand | Teal Wand vaginal self-collection device | Roche cobas Primary HPV test | Company states authorized by the US FDA | Telehealth visit with a Teal Medical provider, kit mailed home, results to clinician |
| Onclarity Self-Collection Kit | Onclarity HPV Self-Collection Kit | BD Onclarity HPV Assay | FDA cleared kit; FDA approved assay (8 April 2026) | Prescription kit mailed to home, lab-processed on BD COR System, results to clinician |
Cleared, Approved, and Authorized Regulatory Terminology
Federal regulatory designations for at-home cervical screening separate the physical collection tool from the laboratory assay. Commercial marketing often flattens these terms into a single label. The statutory definitions carry distinct legal meanings.
Teal Health states that its Teal Wand vaginal sample self-collection device is authorized by the US FDA. This specific designation applies to the physical collection device rather than the underlying molecular test. Analysis of the Teal Wand sample is conducted using the Roche cobas Primary HPV test.
For the alternative route, the FDA cleared the Onclarity HPV Self-Collection Kit. Simultaneously, the FDA approved the BD Onclarity HPV Assay for at-home use with extended genotyping capabilities. The kit functions as the cleared collection vehicle. The assay serves as the approved diagnostic engine. Keeping these components distinct prevents confusion when reviewing device credentials.
| System Component | Teal Health Pathway | Waters Corporation Pathway |
|---|---|---|
| Self-Collection Hardware | Teal Wand device authorized by the US FDA | Onclarity HPV Self-Collection Kit cleared by the FDA |
| Laboratory Molecular Assay | Roche cobas Primary HPV test (laboratory test) | BD Onclarity HPV Assay approved by the FDA for at-home use |
| Automated Processing Platform | Not published | BD COR System fully automated processing |
| Regulatory Status Date | Stated as available in all 50 states (checked October 2026) | Cleared and approved on 8 April 2026 |
Published Accuracy Data Across Both Screening Modalities
Published clinical performance data for at-home HPV screening differs markedly between the two authorized routes. Teal Health publishes specific precancer detection metrics on its platform. The company states the Teal Wand detects cervical precancer 96% of the time, matching clinician collection rates. In supporting notes, Teal Health reports equal detection of CIN2+ cervical dysplasia with a relative sensitivity of 1.00 compared to clinician exams.
A relative sensitivity of 1.00 indicates parity with clinician swabbing in that comparative cohort. It does not mean the device achieves 100% absolute diagnostic sensitivity. By contrast, Waters Corporation published no sensitivity or specificity figures in its regulatory announcement.
Waters Corporation referenced collaboration with the National Cancer Institute on the Cervical Cancer Last Mile Initiative SHIP Trial. That trial evaluated the clinical accuracy of self-collection protocols. Specific numerical outcomes were omitted from the public release.
| Testing Route | Reported Precancer Detection | Relative Sensitivity | Referenced Research Study |
|---|---|---|---|
| Teal Wand | 96% precancer detection (company-stated) | Relative sensitivity 1.00 for CIN2+ dysplasia vs clinician | Internal comparative validation cited on company platform |
| Onclarity Kit | No numerical detection rate published | No sensitivity or specificity figures reported | National Cancer Institute Cervical Cancer Last Mile Initiative SHIP Trial |
Prescription, Telehealth and Availability
Neither authorized at-home HPV test can be purchased directly without a clinician prescription. Self-collection operates within formal medical practice standards.
Patients using Teal Health must schedule and complete a virtual medical appointment with a Teal Medical provider. Following that telehealth intake, the prescription is authorized and the collection kit ships by mail. Teal Health states that its service is available across all 50 states (checked October 2026).
The Waters Corporation Onclarity kit also requires a healthcare provider order. Once ordered, the kit is mailed directly to the individual's home. The patient completes self-collection and mails it to a laboratory. Laboratory staff process the specimen on the automated BD COR System. Waters Corporation announced on 8 April 2026 that the Onclarity kit was expected to become available by prescription in coming months. As of 14 October 2026, broad distribution remains an active rollout objective rather than confirmed universal access.
Cost and Coverage, Without a Price
Neither manufacturer lists an exact retail dollar price for self-collected HPV screening kits. Out-of-pocket expenses depend on insurance plan structures and billing terms.
Teal Health notes that kit expenses qualify for Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). The company states it works with major commercial insurance carriers and offers a direct cash-pay pathway with shipping included. Teal Health explicitly states it cannot service Medicaid or Medi-Cal patients, even under cash-pay terms.
In contrast, Waters Corporation states the Onclarity kit is covered by private insurance, Medicaid, and Medicare. The announcement does not disclose laboratory copay schedules or out-of-pocket maximums. Cervical cancer screening represents an established covered preventive service under most US commercial insurance policies, as outlined in our preventive health screening review.
Clinical Guideline Divergence and Professional Recommendations
Professional medical bodies agree on the underlying cause of cervical neoplasia while maintaining divergent screening intervals. A clinical discussion published in the Annals of Internal Medicine (DOI 10.7326/annals-26-02904, 13 October 2026) addressed these conflicting standards. That exchange between a primary care physician and an obstetrician-gynecologist was highlighted by MedicalXpress.
Both clinicians agreed on foundational principles. Persistent infection with high-risk HPV represents the primary biological driver of cervical cancer. Both experts agreed that raising screening participation across eligible populations remains a major public health priority. Disagreements emerge when translating evidence into screening policies.
Guidance from the American Cancer Society, the Women's Preventive Services Initiative, and the draft U.S. Preventive Services Task Force recommendations generally favor primary HPV testing. However, these organizations differ regarding screening start ages, preferred testing protocols for younger individuals, and the clinical adoption of self-collected samples. The U.S. Preventive Services Task Force guidance currently circulating remains in draft status.
Clinical Follow-Up Requirements After a Positive Result
A positive at-home HPV screening result detects viral genetic material and does not constitute a cancer diagnosis. Laboratory platforms identify high-risk viral DNA sequences. Test results return directly to the prescribing healthcare professional.
In the Annals of Internal Medicine case analysis, both participating clinicians emphasized that unresolved questions persist regarding optimal management following a positive self-collected test. Standardized post-collection algorithms and appropriate retesting intervals remain active subjects of clinical discussion. An abnormal result requires in-person medical evaluation to establish appropriate diagnostic next steps. Patients should never attempt to interpret molecular screening data without physician guidance.
Who Self-Collection Is Aimed At
In the Annals of Internal Medicine analysis, both clinical experts noted that self-collection has the potential to improve access and narrow persistent healthcare disparities. The discussion highlights the need to balance test performance, patient preferences, and health system realities.
Prescription-gated screening models require clinical oversight. Eligibility to self-collect is determined directly by the prescribing clinician.
Our evaluation would change if Teal Health or Waters Corporation release peer-reviewed longitudinal specificity data, if public insurance coverage achieves nationwide consistency, or if guideline bodies finalize standardized home follow-up pathways. If you are overdue for routine cervical screening, speak with your healthcare provider to determine whether a self-collection kit fits your clinical history.
Frequently Asked Questions
Are at-home HPV tests accurate?
Published accuracy varies between available products. Teal Health reports that the Teal Wand detects cervical precancer 96% of the time, matching clinician collection accuracy. The company cites a relative sensitivity of 1.00 for detecting CIN2+ cervical dysplasia compared to clinician swabbing, which indicates equal detection within that evaluation cohort rather than 100% absolute accuracy. Waters Corporation has not published numerical sensitivity or specificity rates for its Onclarity kit, though it references data from the National Cancer Institute Cervical Cancer Last Mile Initiative SHIP Trial. Both pathways use laboratory assays, including the Roche cobas Primary HPV test and the BD Onclarity HPV Assay, to identify viral DNA.
Are at-home HPV tests FDA approved?
Regulatory terms differ between the collection tool and the laboratory assay. Teal Health states that the Teal Wand vaginal sample self-collection device is authorized by the US FDA. Waters Corporation announced that the FDA cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay for at-home collection on 8 April 2026. In both instances, federal scrutiny addressed specific elements of the testing workflow rather than granting a single blanket approval across the entire service. The collection devices gather vaginal samples, while laboratories perform molecular analysis using cleared or approved testing platforms.
How much does an at-home HPV test cost?
Neither Teal Health nor Waters Corporation publishes a set cash retail price for their at-home HPV tests. Teal Health states that its testing services are eligible for Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA), that it accepts major private insurance plans, and that cash pay options include shipping. However, Teal Health explicitly notes that it cannot service patients covered by Medicaid or Medi-Cal, even on a self-pay basis. Waters Corporation reports that the Onclarity kit is covered by private insurance, Medicaid, and Medicare, but has not published an out-of-pocket fee schedule.
Do you need a prescription for an at-home HPV test?
Both authorized at-home HPV testing routes require a prescription from a licensed healthcare clinician. They are not direct-to-consumer or over-the-counter retail kits. For Teal Health, patients schedule a virtual telehealth visit with a Teal Medical provider to establish clinical eligibility before a kit is mailed. Waters Corporation announced that the Onclarity kit is expected to be distributed by prescription through healthcare provider partnerships. In both workflows, a healthcare provider authorizes the prescription and receives the report directly from the laboratory to guide follow-up care.
Is an at-home HPV test the same as a Pap smear?
An at-home HPV test is not the same as a Pap smear. A Pap smear relies on cervical cytology, whereas an at-home test collects a vaginal sample for laboratory HPV testing. An at-home HPV test collects vaginal fluid using a swab or wand, which a laboratory analyzes using molecular assays to identify genetic material from high-risk HPV strains. While cytology evaluates cells directly, high-risk HPV infection is the primary driver of cervical cancer. Guideline groups generally favor primary HPV testing.
Who reads the result, and what happens if it is positive?
Test results are processed on automated laboratory platforms, such as the BD COR System or Roche cobas instruments, and transmitted directly to the ordering clinician. An abnormal or positive result indicates the presence of high-risk viral genetic material; it does not mean you have cervical cancer. In a clinical case review published in the Annals of Internal Medicine, medical experts noted that questions remain regarding optimal clinical follow-up pathways after positive self-collected results. If your test returns positive, an abnormal result still requires in-person follow-up directed by your clinician.
Is an at-home HPV test covered by insurance?
Coverage depends on the specific testing route and your health plan. Cervical cancer screening is an established preventive health benefit covered under most commercial insurance plans in the United States. Waters Corporation states that the Onclarity kit is covered by private insurance, Medicare, and Medicaid. Teal Health states that its service works with major commercial insurers and qualifies for HSA and FSA reimbursement, but explicitly notes that it cannot accept Medicaid or Medi-Cal patients under any billing arrangement. Neither manufacturer publishes a price, so exact out-of-pocket costs must be confirmed with the provider.
Can an at-home HPV test replace going to the clinic for cervical screening?
An at-home HPV test provides an alternative method for collecting a screening specimen, but it does not replace comprehensive clinical care. Major medical guideline bodies, including the American Cancer Society, the Women's Preventive Services Initiative, and the draft U.S. Preventive Services Task Force, disagree on exact screening start ages and how self-collection should be integrated into standard practice. Furthermore, if an at-home test identifies high-risk viral DNA, you must visit a clinic for follow-up evaluation. Self-collection serves to expand screening access for those facing barriers, but in-person medical care remains required whenever abnormal results occur.